Pharmacy No. 84. Delivery of medicines to your home and office.

Medicines

my basket

Apteka84.kz is an online pharmacy that offers its customers medicines, medicinal and decorative cosmetics, dietary supplements, vitamins, baby food, intimate products for adults, medical equipment and thousands of other medical and cosmetic products at low prices. All data presented on the Apteka84.kz website is for informational purposes only and is not a substitute for professional medical care. Apteka84.kz strongly recommends that you carefully read the instructions for use contained in each package of medicines and other products. If you currently have any symptoms of the disease, you should seek help from a doctor. You should always tell your doctor or pharmacist about all the medicines you take. If you feel you need further help, please consult your local pharmacist or contact our GP online or by telephone.

Torasemide

The frequency of the side effects listed below was determined according to the following (World Health Organization classification): very common (more than 10%); often (more than 1% and less than 10%); uncommon (more than 0.1% and less than 1%); rare (more than 0.01% and less than 0.1%); very rarely (less than 0.01%), including isolated reports; frequency unknown (cannot be estimated from available data).

From the blood and lymphatic system

Frequency unknown

- thrombocytopenia, leukopenia, agranulocytosis, aplastic or hemolytic anemia.

Metabolism and nutrition

Infrequently

- hypercholesterolemia, hypertriglyceridemia.

Frequency unknown

- decreased glucose tolerance (possible manifestation of latent diabetes mellitus).

From the nervous system

Often -

dizziness, headache, drowsiness;
infrequently -
muscle cramps of the lower extremities;
frequency is unknown
- confusion, fainting, paresthesia in the extremities (feeling of numbness, “crawling” and tingling).

From the side of the organ of vision

Frequency unknown -

visual impairment.

Hearing and labyrinth disorders

Frequency not known? 1a —

Hearing impairment, tinnitus and hearing loss (usually reversible) usually occur in patients with renal failure or hypoproteinemia (nephrotic syndrome).

From the cardiovascular system

Infrequently -

extrasystole, tachycardia, increased heartbeat, facial flushing;
frequency not known -
excessive arterial hypotension, orthostatic hypotension, collapse, deep vein thrombosis, thromboembolism, hypovolemia.

From the respiratory system

Infrequently -

nosebleeds.

From the digestive system

Often

- diarrhea;
uncommon
- abdominal pain, flatulence, polydipsia;
frequency is unknown -
dry mouth, nausea, vomiting, loss of appetite, pancreatitis, dyspeptic symptoms, intrahepatic cholestasis.

From the kidneys and urinary tract

Often -

increased frequency of urination, polyuria, nocturia;
infrequently -
frequent urge to urinate;
frequency unknown
- oliguria, urinary retention (in patients with urinary tract obstruction), interstitial nephritis, hematuria, increased concentrations of urea and creatinine in the blood.

From the genital organs

Frequency unknown

- violation of potency.

General and administration site disorders

Infrequently

- asthenia (exhaustion), thirst, weakness, increased fatigue, hyperactivity, nervousness.

Laboratory indicators

Infrequently -

increase in platelet count;
frequency unknown -
hyperglycemia, hyperuricemia, decrease in the number of red blood cells, leukocytes and platelets, a slight increase in the activity of alkaline phosphatase in the blood, increased activity of some liver enzymes (for example, gamma-glutamyl transferase).

From the skin and subcutaneous tissues

Frequency unknown

- skin itching, rash, urticaria, erythema multiforme, exfoliative dermatitis, purpura, vasculitis, photosensitivity.

From the musculoskeletal system

Frequency unknown

- muscle weakness.

From the side of water-electrolyte and acid-base balance

Frequency unknown

- hyponatremia, hypochloremia, hypokalemia, hypomagnesemia, hypocalcemia, metabolic alkalosis. Symptoms indicating the development of electrolyte and acid-base disorders may include headache, confusion, convulsions, tetany, muscle weakness, cardiac arrhythmias and dyspeptic disorders; hypovolemia and dehydration (more often in elderly patients), which can lead to hemoconcentration with a tendency to develop thrombosis.

If any of the side effects indicated in the instructions get worse ,
or you notice any other side effects not listed in the instructions, tell your doctor.

Torsemide, 5 mg, tablets, 60 pcs.

The drug LOTONEL® is used strictly as prescribed by a doctor.

Patients with hypersensitivity to sulfonamides and sulfonylureas may have cross-sensitivity to torsemide.

For patients receiving high doses of torasemide over a long period, a diet with sufficient salt content and the use of potassium supplements are recommended to avoid the development of hyponatremia, hypokalemia and metabolic alkalosis.

The risk of hypokalemia is greatest in patients with liver cirrhosis, increased diuresis, insufficient dietary electrolytes, and concomitant use of corticosteroids or ACTH.

An increased risk of developing fluid and electrolyte imbalances is observed in patients with renal failure. During a course of treatment with LOTONEL®, it is necessary to periodically monitor the content of electrolytes in the blood plasma (including sodium, calcium, potassium, magnesium), acid-base status, concentration of residual nitrogen, creatinine, uric acid and, if necessary, carry out appropriate corrective therapy ( with a higher frequency in patients with frequent vomiting and against the background of parenteral administration of fluids).

In patients who have developed fluid and electrolyte disturbances, hypovolemia, or prerenal azotemia, laboratory findings may include: hyper- or hyponatremia, hyper- or hypochloremia, hyper- or hypokalemia, acid-base imbalance, and increased plasma urea concentrations. If these deviations from laboratory parameters occur, it is necessary to stop taking LOTONEL® until normal values are restored, and then resume treatment with LOTONEL® at a lower dose.

If azotemia and oliguria appear or worsen in patients with severe progressive kidney disease, it is recommended to suspend treatment with LOTONEL®.

The selection of a dosage regimen for patients with ascites against the background of liver cirrhosis should be carried out in a hospital setting (violations of water and electrolyte balance can lead to the development of hepatic coma). This category of patients requires regular monitoring of blood plasma electrolytes.

The use of the drug LOTONEL® may cause an exacerbation of gout.

In patients with diabetes mellitus or with reduced glucose tolerance, periodic monitoring of glucose concentrations in the blood and urine is required.

In unconscious patients with benign prostatic hyperplasia and narrowing of the ureters, diuresis control is necessary due to the possibility of acute urinary retention.

In patients with diseases of the cardiovascular system, especially those taking cardiac glycosides, diuretic-induced hypokalemia can cause the development of arrhythmias.

Impact on the ability to drive vehicles and machinery

During the treatment period, patients should refrain from driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions (risk of dizziness and drowsiness).

Torasemide

Blood and lymphatic system disorders: frequency unknown: thrombocytopenia, leukopenia, agranulocytosis, aplastic or hemolytic anemia.

Metabolic and nutritional disorders: uncommon: polydipsia, hypercholesterolemia, hypertriglyceridemia; frequency unknown: decreased glucose tolerance (possible manifestation of latent diabetes mellitus).

Nervous system disorders: often: dizziness, headache, drowsiness; uncommon: muscle cramps of the lower extremities; frequency unknown: confusion, fainting, paresthesia in the extremities (feeling of numbness, crawling and tingling).

Visual disorders: frequency unknown: visual impairment.

Hearing and labyrinthine disorders: frequency unknown: hearing impairment, tinnitus and hearing loss (usually reversible) usually in patients with renal failure or hypoproteinemia (nephrotic syndrome).

Cardiac disorders: uncommon: extrasystole, arrhythmia, tachycardia.

Vascular disorders: frequency unknown: excessive decrease in blood pressure, orthostatic hypotension, collapse, deep vein thrombosis, thromboembolism.

Respiratory, thoracic and mediastinal disorders: uncommon: nosebleeds.

Gastrointestinal disorders: often: diarrhea; uncommon: abdominal pain, flatulence; frequency unknown: dry mouth, nausea, vomiting, loss of appetite, pancreatitis, dyspeptic disorders.

Liver and biliary tract disorders: frequency unknown: intrahepatic cholestasis.

Skin and subcutaneous tissue disorders: frequency unknown: pruritus, rash, urticaria, erythema multiforme, exfoliative dermatitis, purpura, vasculitis, photosensitivity.

Musculoskeletal and connective tissue disorders: frequency unknown: muscle weakness.

Renal and urinary tract disorders: often: increased frequency of urination, polyuria, nocturia; uncommon: increased urge to urinate; frequency unknown: oliguria, urinary retention (in patients with urinary tract obstruction), interstitial nephritis, hematuria.

Disorders of the genital organs and breast: frequency unknown: decreased potency.

General disorders and administration site disorders: uncommon: fever, asthenia, weakness, fatigue, hyperactivity, nervousness. Severe anaphylactic reactions up to shock, which until now have only been described after intravenous administration.

Laboratory and instrumental data: frequency unknown: hypercholesterolemia, hypertriglyceridemia, hyperuricemia, a slight increase in the concentration of alkaline phosphatase in the blood, a transient increase in the concentration of creatinine and urea in the blood, an increase in the activity of some “liver” enzymes (for example, gamma-glutamyl transferase).

Disorders of water-electrolyte and acid-base balance: frequency unknown: hypokalemia, hyponatremia, hypomagnesemia, hypocalcemia, hypochloremia, metabolic alkalosis, hypovolemia, dehydration (more often in elderly patients), which can lead to hemoconcentration with a tendency to develop blood clots.

In case of overdose, the following symptoms may develop: excessively increased diuresis, accompanied by a decrease in circulating blood volume (CBV) and an imbalance in the electrolyte balance of the blood, followed by a pronounced decrease in blood pressure, drowsiness and confusion, collapse. Gastrointestinal disturbances may occur.

A specific antidote is unknown. Vomiting is induced, gastric lavage is performed, and activated charcoal is prescribed. Treatment is symptomatic, dose reduction or discontinuation of the drug and at the same time replenishment of blood volume and indicators of water-electrolyte balance and acid-base status under the control of serum concentrations of electrolytes, hematocrit. Hemodialysis is not effective, since the elimination of torasemide and its metabolites is not accelerated.